Business
Mettrum Health Corp. sponsorship of Current Oncology sheds light on the benefit of cannabis for cancer patients.
Mettrum Health Corp. sponsorship of Current Oncology sheds light on the benefit of cannabi...
About this update from M3 Metals Corp.
[{"type":"text","content":"\n\n\n\nMettrum Health Corp. sponsorship of Current Oncology sheds light on the benefit of cannabis for cancer patients.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMettrum Health Corp. sponsorship of Current Oncology sheds light on the benefit of cannabis for cancer patients.\nCanada NewsWire\nTORONTO, April 5, 2016\n\n\n\nTORONTO, April 5, 2016 /CNW/ - Mettrum Health Corp. (\"Mettrum\" or the \"Company\") (TSXV:MT), a vertically integrated producer of cannabis products, is proud to be the exclusive sponsor of a special issue of Current Oncology that highlights the use of cannabis for cancer patients. The supplement is aimed at informing the oncological community in Canada about the role that medical cannabis and cannabinoids can play in cancer management. The special issue is guest edited by Dr. Mark Ware, Director of Clinical Research, Alan Edwards Pain Management Unit, McGill University Health Centre, and Executive Director of the non-profit Canadian Consortium for the Investigation of Cannabinoids (CCIC).\n\n\"Finding answers to the questions regarding cannabis and cancer will require a concerted effort by patients, scientists, clinicians and the industry,\" said Dr. Mark Ware. \"We at CCIC are proud to have stimulated this discussion, and we urge all stakeholders to move forward with the needed research to address an issue that really is a matter of life and death.\" \n\nThe treatment of cancer and its symptoms has been recognized as one of the most critical advances in cannabinoid therapeutics. \"This issue brings together the work of some of the leading minds around the world who have dedicated themselves and their laboratories to understanding the role of cannabis and cannabinoids in the pathophysiology and management of cancer.  This collection of papers takes us on a journey from bedside to bench and back, and provides a series of important signposts that will help to chart a path to better cancer care,\" said Dr. Ware. Print copies of this supplement will be sent to Current Oncology's 3,200 subscribers. It is also available online, for free...